This was recently investigated by the METTEN study, which examined whether metformin was able to increase the pathological complete response (clearance of cancer) in HER2-positive breast cancers treated with traditional chemotherapeutics + trastuzumab [103]. This evidence concerns the gene ERBB2 and breast carcinoma.